Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA® (pembrolizumab)

NEXT STORY
Humacyte Highlights Robust Expanded Access Program and Patient Testimonial for Human Acellular Vessels
PREV STORY
Global Direct-to-Consumer Genetic Testing Market: Focus on Direct-to-Consumer Genetic Testing Market by Product Type, Distribution Channel, 15 Countries Mapping, and Competitive Landscape – Analysis and Forecast, 2021-2031
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Microbot Medical’s Self-Cleaning Shunt (SCS™) Clearly Demonstrated the Ability to Prevent Shunt Occlusion in a Follow-up In-vitro Laboratory Study

author_avatar
NASDAQ Market News

Terveystalo Plc: Proposals of the Shareholders Nomination Board to the Annual General Meeting 2019

Terveystalo Plc Stock Exchange Release 30 January 2019 at 13:00 EET The Shareholders' Nomination ...

author_avatar
NASDAQ Market News

Vifor Pharma continues commitment to raise awareness of iron deficiency

The 12th ECCO Congress that took place in Barcelona, Spain, from 15 to 18 ...

author_avatar
NASDAQ Market News